Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 3/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 5/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990690 | 0.98 | DDR2 (0.61) | DDR2GSK3BRAF1P2RX3KDR | |
| SCHEMBL16990624 | 0.96 | DDR2 (0.67) | DDR2GSK3BRAF1P2RX3KDR | |
| SCHEMBL16990651 | 0.93 | DDR2 (0.63) | DDR2GSK3BRAF1P2RX3KDR | |
| SCHEMBL171214 | 0.92 | DDR2 (0.60) | DDR2GSK3BRAF1KDR | |
| SCHEMBL15575367 | 0.90 | DDR2 (0.60) | DDR2GSK3BRAF1KDR | |
| SCHEMBL15575235 | 0.90 | DDR2 (0.57) | DDR2GSK3BRAF1P2RX3KDR | |
| SCHEMBL16990611 | 0.90 | DDR2 (0.54) | DDR2GSK3BRAF1P2RX3 | |
| SCHEMBL16990733 | 0.89 | DDR2 (0.54) | DDR2GSK3BRAF1P2RX3 | |
| SCHEMBL171021 | 0.88 | DDR2 (0.65) | DDR2GSK3BRAF1KDR | |
| SCHEMBL15574590 | 0.88 | DDR2 (0.79) | DDR2GSK3BRAF1P2RX3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885GSK3B 494/4885RAF1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.